In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo

Thomas G. DeLoughery

doi:10.7326/J23-0014

In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

SOURCE CITATION: Ageno W, Bertu L, Bucherini E, et al; RIDTS study group. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022;379:e072623. 36520715.

Original language	English (US)
Pages (from-to)	JC42
Journal	Annals of internal medicine
Volume	176
Issue number	4
DOIs	https://doi.org/10.7326/J23-0014
State	Published - Apr 2023

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.7326/J23-0014

Cite this

@article{3555807cd4044b4fbf65ef7e4744d08b,

title = "In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo",

abstract = "SOURCE CITATION: Ageno W, Bertu L, Bucherini E, et al; RIDTS study group. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022;379:e072623. 36520715.",

author = "DeLoughery, {Thomas G.}",

year = "2023",

month = apr,

doi = "10.7326/J23-0014",

language = "English (US)",

volume = "176",

pages = "JC42",

journal = "Annals of internal medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "4",

}

TY - JOUR

T1 - In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo

AU - DeLoughery, Thomas G.

PY - 2023/4

Y1 - 2023/4

N2 - SOURCE CITATION: Ageno W, Bertu L, Bucherini E, et al; RIDTS study group. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022;379:e072623. 36520715.

AB - SOURCE CITATION: Ageno W, Bertu L, Bucherini E, et al; RIDTS study group. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022;379:e072623. 36520715.

UR - http://www.scopus.com/inward/record.url?scp=85152630150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152630150&partnerID=8YFLogxK

U2 - 10.7326/J23-0014

DO - 10.7326/J23-0014

M3 - Comment/debate

C2 - 37011394

AN - SCOPUS:85152630150

SN - 0003-4819

VL - 176

SP - JC42

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 4

ER -

In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this